Literature DB >> 7000102

Captopril in clinical hypertension. Changes in components of renin-angiotensin system and in body composition in relation to fall in blood pressure with a note on measurement of angiotensin II during converting enzyme inhibition.

A B Atkinson, J J Morton, J J Brown, D L Davies, R Fraser, P Kelly, B Leckie, A F Lever, J I Robertson.   

Abstract

The effect of the converting enzyme inhibitor captopril on arterial pressure, the components of the renin-angiotensin-aldosterone system, and body sodium and potassium content was studied in eight hypertensive patients with renal artery stenosis and, in conjunction with diuretics, in seven patients with hypertension unresponsive to previous treatment. Two hours after the first dose, captopril caused significant falls in systolic and diastolic pressures, plasma angiotensin II, and aldosterone, with converse increases in angiotensin I and both active and total renin; the initial fall in diastolic pressure was significantly related to the drop in plasma angiotensin II. The biochemical changes were sustained during prolonged treatment, even when diuretics were added. One untreated patient with renal artery occlusion had severe secondary aldosterone excess, was sodium and potassium depleted, and severely hyponatraemic and hypokalaemic; captopril restored blood pressure, plasma electrolyte concentrations, and exchangeable sodium and total body potassium to normal. In one man with renal artery stenosis and overall renal impairment captopril led to sodium retention, and blood pressure did not fall until a diuretic was added. In the remaining patients with renal artery stenosis, pretreatment renin, angio tensin II, and aldosterone concentrations were either normal or only modestly raised, and plasma electrolyte concentrations and body content of sodium and potassium were normal. Captopril alone controlled arterial pressure in all, three cases showing a gradual fall of pressure over the first six weeks of treatment; no significant changes in exchangeable sodium or total body potassium were seen. The group of patients with previously intractable hypertension were all controlled with a combination of captopril and diuretic.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7000102      PMCID: PMC482400          DOI: 10.1136/hrt.44.3.290

Source DB:  PubMed          Journal:  Br Heart J        ISSN: 0007-0769


  22 in total

1.  Unilateral renal artery obstruction associated with malignant nephrosclerosis confined to the opposite kidney.

Authors:  H BAUER; L FORBES
Journal:  Am Heart J       Date:  1952-10       Impact factor: 4.749

2.  Hypertension in chronic renal failure. An abnormal relation between sodium and the renin-angiotensin system.

Authors:  M A Schalekamp; D G Beevers; J D Briggs; J J Brown; D L Davies; R Fraser; M Lebel; A F Lever; A Medina; J J Morton; J I Robertson; M Tree
Journal:  Am J Med       Date:  1973-09       Impact factor: 4.965

3.  Interruption of the renin-angiotensin system in hypertensive patients by captopril induces sustained reduction in aldosterone secretion, potassium retention and natruiresis.

Authors:  S A Atlas; D B Case; J E Sealey; J H Laragh; D N McKinstry
Journal:  Hypertension       Date:  1979 May-Jun       Impact factor: 10.190

4.  Captopril in hypertension with renal artery stenosis and in intractable hypertension; acute and chronic changes in circulating concentrations of renin, angiotensins I and II and aldosterone, and in body composition.

Authors:  A B Atkinson; J J Brown; R Fraser; B Leckie; A F Lever; J J Morton; J I Robertson
Journal:  Clin Sci (Lond)       Date:  1979-12       Impact factor: 6.124

5.  Abnormal relation between exchangeable sodium and the renin-angiotensin system in malignant hypertension and in hypertension with chronic renal failure.

Authors:  D L Davies; D G Beevers; J D Briggs; A M Medina; J I Robertson; M A Schalekamp; J J Brown; A F Lever; J J Morton; M Tree
Journal:  Lancet       Date:  1973-03-31       Impact factor: 79.321

6.  Angiotensins I and II in renal vein blood.

Authors:  P F Semple; A M Cumming; J A Millar
Journal:  Kidney Int       Date:  1979-03       Impact factor: 10.612

7.  Long-term effects of captopril (SQ14 225) on blood-pressure and hormone levels in essential hypertension.

Authors:  C I Johnston; J A Millar; B P McGrath; P G Matthews
Journal:  Lancet       Date:  1979-09-08       Impact factor: 79.321

Review 8.  Angiotensin II and renal hypertension in dog, rat and man: effect of converting enzyme inhibition.

Authors:  A B Atkinson; J J Brown; R Fraser; A F Lever; J J Morton; A J Riegger; J I Robertson
Journal:  Clin Exp Hypertens       Date:  1980       Impact factor: 1.749

9.  Concurrent estimation of total body and exchangeable body sodium in hypertension.

Authors:  K Boddy; J J Brown; D L Davies; A Elliott; I Harvey; J K Haywood; I Holloway; A F Lever; J I Robertson; E D Williams
Journal:  Clin Sci Mol Med       Date:  1978-02

10.  Correction of renal hypertension in the rat by prolonged infusion of angiotensin inhibitors.

Authors:  A J Riegger; A F Lever; J A Millar; J J Morton; B Slack
Journal:  Lancet       Date:  1977 Dec 24-31       Impact factor: 79.321

View more
  23 in total

1.  Laboratory investigation of primary aldosteronism.

Authors:  Michael Stowasser; Paul J Taylor; Eduardo Pimenta; Ashraf H Al-Asaly Ahmed; Richard D Gordon
Journal:  Clin Biochem Rev       Date:  2010-05

2.  Regression of a large congenital hepatic arteriovenous malformation.

Authors:  Hala Mounir Agha; Rania Zakaria; Fatma Alzahraa Mostafa; Hala Hamza
Journal:  Tex Heart Inst J       Date:  2015-04-01

Review 3.  Vascular haemodynamic effects of perindopril in essential hypertension.

Authors:  W Littler
Journal:  Drugs       Date:  1990       Impact factor: 9.546

Review 4.  ACE inhibitors for heart failure: a question of dose.

Authors:  J G Cleland; P A Poole-Wilson
Journal:  Br Heart J       Date:  1994-09

5.  Effect of captopril on renal function in patients with congestive heart failure.

Authors:  G L Pierpont; G S Francis; J N Cohn
Journal:  Br Heart J       Date:  1981-11

6.  Haemodynamic profile of captopril treatment in various forms of hypertension.

Authors:  J H de Bruyn; A J Man in't Veld; G J Wenting; F H Derkx; M A Schalekamp
Journal:  Eur J Clin Pharmacol       Date:  1981       Impact factor: 2.953

7.  Captopril treatment: inter-dose variations in renin, angiotensins I and II, aldosterone and blood pressure.

Authors:  A B Atkinson; A M Cumming; J J Brown; R Fraser; B Leckie; A F Lever; J J Morton; J I Robertson
Journal:  Br J Clin Pharmacol       Date:  1982-06       Impact factor: 4.335

8.  Captopril in heart failure. A double blind controlled trial.

Authors:  J G Cleland; H J Dargie; G P Hodsman; S G Ball; J I Robertson; J J Morton; B W East; I Robertson; G D Murray; G Gillen
Journal:  Br Heart J       Date:  1984-11

9.  Enalapril (MK421) and its lysine analogue (MK521): a comparison of acute and chronic effects on blood pressure, renin-angiotensin system and sodium excretion in normal man.

Authors:  G P Hodsman; J R Zabludowski; C Zoccali; R Fraser; J J Morton; G D Murray; J I Robertson
Journal:  Br J Clin Pharmacol       Date:  1984-03       Impact factor: 4.335

10.  Converting-enzyme inhibitor enalapril (MK421) in treatment of hypertension with renal artery stenosis.

Authors:  G P Hodsman; J J Brown; D L Davies; R Fraser; A F Lever; J J Morton; G D Murray; J I Robertson
Journal:  Br Med J (Clin Res Ed)       Date:  1982-12-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.